en · de · es · fr · pt
ipamorelin-notes.peptides4088.com › News › Ipamorelin Background And Pharmacology — Background and Details

Ipamorelin Background And Pharmacology — Background and Details

By Editorial Desk · published 2026-02-28 · last reviewed 2026-03-21 · News

If you have been reading about electrospray ionisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-03-21. Where a claim depends on a specific study, the study is described rather than over-claimed.

Ipamorelin Background and Pharmacology

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.

At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.

Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.

Background and Structural Identity

The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.

Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.

Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.

Ipamorelin at a glance

PropertyValueNotes
Chemical classSynthetic pentapeptideGrowth hormone secretagogue family
SequenceAib-His-D-2-Nal-D-Phe-Lys-NH2Contains two non-natural residues
Molecular formulaC38H49N9O5Free base form
Molecular weight711.85 g/molCalculated from formula
Primary targetGHS-R1a ghrelin receptorAgonist activity

Handling, Storage, and Analytics

Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.

Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.

Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.

Related pages on this site

Analytical Characterisation and Storage

Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.

Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.

The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.

Further detail

=== Doubling time === The doubling time is the amount of time it would take for a breeder reactor to produce enough new fissile material to replace the original fuel and additionally produce an equivalent amount of fuel for another nuclear reactor. This was considered an important measure of breeder performance in early years, when uranium was thought to be scarce. However, since uranium is more abundant than thought in the early days of nuclear reactor development, and given the amount of plutonium available in spent reactor fuel, doubling time has become a less important metric in modern breeder-reactor design.

==== Phase II and III ==== Phase II and IIIa trials of the vaccine were carried out at the same time in Bắc Ninh, Hanoi and Long An with a total of 1,000 volunteers. The trial work in the northern localities is carried out by Hanoi Medical University and Pasteur Institute in Ho Chi Minh City in the south. In Bắc Ninh, from 20 to 23 September, the research team started recruiting volunteers and selected 338 people aged 18-65, who received the first dose from 27 to 29 September. In Long An and Hanoi, the Ministry of Health also implemented the first dose for volunteers. The phase IIIa trial is expected to end on 24 November, and the research team will report the results of the trial to the Ministry of Health on 30 December.

In the ensuing power struggle for control over the province, General Wang Zuanxu made a deal with Liu that he would return the Ya'an and Xichang regions to Xikang as well as subsidize the Xikang government with 360,000 yuan per year in exchange for Liu's support. This deal went through, and the central government even agreed to fund a highway from Sichuan to Xikang. On 28 November, 1938, the Executive Yuan ratified the establishment of Xikang Province, which was officially inaugurated on 1 January, 1939. Liu Wenhui became the governor of Xikang. In exchange, Wang Zuanxu was able to become the acting chairman of Sichuan Province, although he failed to secure control and was later usurped by Chiang Kai-shek himself. Liu Wenhui's provincial government was highly nepotistic, made up mostly of personal connections, secretaries, and subordinate officers. Only one politician in the new government, Ye Xiufeng, was a Chiang loyalist: he was subsequently outmaneuvered by Liu and dismissed within two years. Although the Tibetan population were hopeful that the establishment of the province would entail increased representation, Liu only appointed one Tibetan, a monk, to the governing board. This was justified by the national government as a prioritization of national stability over minority rights, ensuring that the Xikang government remained Han-centric and Han-dominant. In addition, the wartime situation meant that by cooperating with the central government, Liu Wenhui would be able to maintain his rule over Xikang.

The research assistant's job can include some or all of the following: providing the local institutional review board (IRB) with the documentation necessary to obtain its permission to conduct the study, assisting with study start-up, identifying eligible patients, obtaining consent from them or their families, administering study treatment(s), collecting and statistically analyzing data, maintaining and updating data files during followup, and communicating with the IRB, as well as the sponsor and CRO.

Sources: en.wikipedia.org

Supporting material

Speer, William (1870). The oldest and the newest empire: China and the United States. Hartford, Conn., S. S. Scranton and company; Philadelphia, Parmelee & co.; [etc., etc.] Thelwall, A. S. (1839). The iniquities of the opium trade with China; being a development of the main causes which exclude the merchants of Great Britain from the advantages of an unrestricted commercial intercourse with that vast empire. With extracts from authentic documents. London : Wm. H. Allen and Co. Turner, Frederick Storrs (1876). British opium policy and its results to India and China. London, S. Low, Marston, Searle, & Rivington. Matthee RP (2005). The Pursuit of Pleasure: Drugs and Stimulants in Iranian History, 1500–1900. Princeton, New Jersey: Princeton University Press. ISBN 978-0691118550.

Israel say the refusal was because they intended to spread hate speech against Israel. Elin Jones confirms she will stand down as Llywydd of the Senedd following the next election. 8 April – Downing Street declines calls to officially back a campaign to buy British goods in the wake of the introduction of US trade tariffs, arguing that the UK is "an open-trading nation" and the government is "not going to tell people where they buy their stuff". The European Court of Human Rights rules that businessman Sir Philip Green's human rights were not breached when he was named in the House of Lords in relation to misconduct allegations in 2018. He was named in Parliament under the rule of Parliamentary privilege, which allows Members of Parliament and peers to speak without the threat of legal repercussions. 9 April King Charles gives a speech to the Italian Parliament. He and Queen Camilla also have a private meeting with Pope Francis at Vatican City. Leader of the Fire Brigades Union Steve Wright calls on Labour MPs to reject benefit cuts. Councillor for Talbot and Branksome Woods on Bournemouth, Christchurch and Poole Council Karen Rampton resigns from the Conservative Party. The Welsh Government confirms that the Senedd will vote on whether the Terminally Ill Adults (End of Life) Bill should apply to Wales if it successfully passes through the Westminster parliament. 10 April – The Cabinet Office is to lose a third of its posts as part of government reforms to the civil service, with 2,100 of the 6,500 positions to be cut.

In July 2015, Allergan agreed to sell its generic drug business (Actavis Generics) to Teva for $40.5 billion ($33.75 billion in cash and $6.75 billion worth of shares). As a result, Teva dropped its pursuit of Mylan. In order for the deal to gain regulatory approval, Teva sold off a number of assets, including a portfolio of five generic drugs to Sagent Pharmaceuticals for $40 million, as well as a further eight medicines to Dr. Reddy's in a $350 million deal. Teva also sold a further 15 marketed generics, as well as three others that were close to market, for $586 million to Impax Laboratories. In July, Teva sold off a further 42 products to Australian generics company, Mayne Pharma, for $652 million; the deal moved Mayne up 50 spots, into the top-25 companies of US generic companies. As part of the deal Teva will seek to raise $20 to $25 billion through a bond sale. After completing the $39 billion acquisition of Actavis Generics, Teva announced another, smaller, deal with Allergan, agreeing to acquire its generic distribution business Anda for $500 million.

Sources: en.wikipedia.org

Notes from published material

==== Indonesia ==== In 2008, 7-Eleven announced plans to expand its business in Indonesia through a master franchise agreement with Modern Sevel Indonesia. Modern Sevel Indonesia's initial plans were to focus on opening stores in Jakarta, targeting densely populated commercial and business areas. There were 190 7-Eleven stores in Indonesia as of 2014 which then reduced to only 166 stores in September 2016. 7-Eleven then closed its doors in Indonesia in 2017, citing low sales.

The government loosened its emphasis on socialist realism; thus, for instance, many protagonists of the novels of author Yury Trifonov concerned themselves with problems of daily life rather than with building socialism. Underground dissident literature, known as samizdat, developed during this late period. In architecture, the Khrushchev era mostly focused on functional design as opposed to the highly decorated style of Stalin's epoch. In music, in response to the increasing popularity of forms of popular music like jazz in the West, many jazz orchestras were permitted throughout the USSR, notably the Melodiya Ensemble, named after the principle record label in the USSR. In the second half of the 1980s, Gorbachev's policies of perestroika and glasnost significantly expanded freedom of expression throughout the country in the media and the press.

Extreme exercise can make capillaries vulnerable, with a breaking point similar to that of collagen. Capillary permeability can be increased by the release of certain cytokines, anaphylatoxins, or other mediators (such as leukotrienes, prostaglandins, histamine, bradykinin, etc.) highly influenced by the immune system.

Sources: en.wikipedia.org

Frequently asked questions

What type of molecule is ipamorelin?

It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.

Which receptor does ipamorelin act on?

It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.

How does it differ from other secretagogues?

Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.

What type of molecule is ipamorelin?

It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.

Network